These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 33860836)

  • 21. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
    Run L; Wang L; Nong X; Li N; Huang X; Xiao Y
    Endocrine; 2021 Feb; 71(2):418-426. PubMed ID: 32666385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphenol A at a human exposed level can promote epithelial-mesenchymal transition in papillary thyroid carcinoma harbouring BRAF
    Li L; Li H; Zhang J; Gao X; Jin H; Liu R; Zhang Z; Zhang X; Wang X; Qu P; Zhao Y; Lu X
    J Cell Mol Med; 2021 Feb; 25(3):1739-1749. PubMed ID: 33469997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
    Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
    J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
    Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
    Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Density Lipoprotein Receptor Is a Key Driver of Aggressiveness in Thyroid Tumor Cells.
    Revilla G; Ruiz-Auladell L; Vallverdú NF; Santamaría P; Moral A; Pérez JI; Li C; Fuste V; Lerma E; Corcoy R; Pitoia F; Escolà-Gil JC; Mato E
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
    Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma.
    Chen X; Lin S; Lin Y; Wu S; Zhuo M; Zhang A; Zheng J; You Z
    J Transl Med; 2022 Feb; 20(1):79. PubMed ID: 35123502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the Role of FRMD5 in the Biology of Papillary Thyroid Carcinoma.
    Gaweł AM; Ratajczak M; Gajda E; Grzanka M; Paziewska A; Cieślicka M; Kulecka M; Oczko-Wojciechowska M; Godlewska M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KCNIP3 silence promotes proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma through activating Wnt/β-catenin pathway.
    Zhong J; Lin R; Wang G; Lin L; Ruan S; Liu W
    Tissue Cell; 2022 Apr; 75():101739. PubMed ID: 35066335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway.
    Zhou Z; Liu Y; Ma M; Chang L
    Biomed Pharmacother; 2017 Dec; 96():98-103. PubMed ID: 28965013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation.
    Cho NL; Lin CI; Whang EE; Carothers AM; Moore FD; Ruan DT
    Thyroid; 2010 Jun; 20(6):615-22. PubMed ID: 20470206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
    Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
    Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
    Dadu R; Shah K; Busaidy NL; Waguespack SG; Habra MA; Ying AK; Hu MI; Bassett R; Jimenez C; Sherman SI; Cabanillas ME
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E77-81. PubMed ID: 25353071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autophagy sustains mitochondrial respiration and determines resistance to BRAF
    Díaz-Gago S; Vicente-Gutiérrez J; Ruiz-Rodríguez JM; Calafell J; Álvarez-Álvarez A; Lasa M; Chiloeches A; Baquero P
    Autophagy; 2024 Jun; 20(6):1383-1397. PubMed ID: 38436206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
    Fu H; Cheng L; Sa R; Jin Y; Chen L
    J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF
    Wen SS; Wu YJ; Wang JY; Ni ZX; Dong S; Xie XJ; Wang YT; Wang Y; Huang NS; Ji QH; Ma B; Qu N
    Thyroid; 2024 Oct; 34(10):1246-1259. PubMed ID: 39162997
    [No Abstract]   [Full Text] [Related]  

  • 39. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.
    Wen D; Liao T; Ma B; Qu N; Shi RL; Lu ZW; Wang YL; Wei WJ; Ji QH
    Cancer Med; 2018 Feb; 7(2):285-296. PubMed ID: 29341469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.